Persistent pulmonary hypertension of the newborn

Semin Fetal Neonatal Med. 2017 Aug;22(4):220-226. doi: 10.1016/j.siny.2017.03.004. Epub 2017 Mar 23.


Failure of the normal circulatory adaptation to extrauterine life results in persistent pulmonary hypertension of the newborn (PPHN). Although this condition is most often secondary to parenchymal lung disease or lung hypoplasia, it may also be idiopathic. PPHN is characterized by elevated pulmonary vascular resistance with resultant right-to-left shunting of blood and hypoxemia. Although the preliminary diagnosis of PPHN is often based on differential cyanosis and labile hypoxemia, the diagnosis is confirmed by echocardiography. Management strategies include optimal lung recruitment and use of surfactant in patients with parenchymal lung disease, maintaining optimal oxygenation and stable blood pressures, avoidance of respiratory and metabolic acidosis and alkalosis, and pulmonary vasodilator therapy. Extracorporeal membrane oxygenation is considered when medical management fails. Although mortality associated with PPHN has decreased significantly with improvements in medical care, there remains the potential risk for neurodevelopmental disability which warrants close follow-up of affected infants after discharge.

Keywords: Bosentan; Hypoxemia; Milrinone; Nitric oxide; Prostacyclin; Sildenafil.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Cyanosis / etiology
  • Cyanosis / physiopathology
  • Cyanosis / prevention & control
  • Diagnosis, Differential
  • Humans
  • Hypertension, Pulmonary / congenital*
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / therapy
  • Hypoxia / etiology
  • Hypoxia / physiopathology
  • Hypoxia / prevention & control
  • Infant, Newborn
  • Models, Biological*
  • Neurodevelopmental Disorders / etiology
  • Neurodevelopmental Disorders / prevention & control
  • Practice Guidelines as Topic